Literature DB >> 3484892

Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.

R Kato, B N Singh.   

Abstract

Bepridil hydrochloride is a relatively new calcium antagonist which appears to have a complex pharmacologic profile, but its concentration-response characteristics with respect to its electrophysiologic properties of varying concentrations (0.1 to 10.0 micrograms/ml) of the drug were therefore determined in rabbit and canine myocardial fiber preparations in vitro by standard microelectrode techniques. The following were measured: sinus cycle length (SCL), action potential amplitude (APA), maximum diastolic potential (MDP), threshold potential (TP), slope of phase 4 depolarization, action potential duration (APD), and dV/dtmax of phase O depolarization (Vmax) in rabbit sinoatrial (SA) node. Also measured were APA, membrane resting potential (MRP), Vmax, APD at 50% and 90% repolarization (APD50 and APD90), and effective refractory period (ERP) in rabbit atria and canine Purkinje fibers and ventricular muscle. At the lowest concentrations bepridil selectively prolonged SCL by reducing the slope of phase 4 and decreased APA and MDP in a concentration-dependent manner in the sinus node. At higher concentrations, bepridil exerted additional effects in producing concentration-dependent decreases in APA and Vmax in rabbit atria and in canine Purkinje fibers and ventricular muscle. During superfusion with 1.0 micrograms/ml bepridil, Vmax fell by 22.2% (p less than 0.05) in Purkinje fibers and by 11.8% (NS) in ventricular muscle; at 10.0 micrograms/ml, Vmax fell by 46.5% (p less than 0.01), respectively. The depression of Vmax was frequency dependent. There was a differential effect of bepridil on repolarization in Purkinje fibers as compared to that in ventricular muscle.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484892     DOI: 10.1016/0002-8703(86)90139-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties.

Authors:  T Osaka; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

2.  Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.

Authors:  J C Wang; T Kiyosue; K Kiriyama; M Arita
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; D Hafner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

4.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

Review 5.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 6.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Comparison of the effects of bepridil and aprindine for the prevention of atrial fibrillation after cardiac and aortic surgery: A prospective randomized study.

Authors:  Mahito Ozawa; Takashi Komatsu; Yoshihiro Sato; Fusanori Kunugita; Hideaki Tachibana; Atsushi Tashiro; Hitoshi Okabayashi; Motoyuki Nakamura
Journal:  J Arrhythm       Date:  2015-05-16

8.  Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel.

Authors:  Ying Wang; Zhijie Fu; Zhiyong Ma; Na Li; Hong Shang
Journal:  Ann Transl Med       Date:  2021-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.